ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1873

Age- and Cause-Specific Standardized Mortality Ratio of Systemic Lupus Erythematosus Patients in Ontario, Canada over 43 Years (1971-2013)

Konstantinos Tselios, Dafna D Gladman, Barry Sheane, Jiandong Su and Murray Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Morbidity and mortality and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: 4M081 ACR Abstract: Edmond L. Dubois, MD Memorial Lecture: SLE–Clinical (1870–1874)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: The major causes of early death in systemic lupus erythematosus (SLE) include active disease and infections, while cardiovascular complications and malignancies dominate the late stages. In recent years, there has been a significant decrease in all-cause mortality. The aim of the present study was to assess the all cause, age and cause-specific standardized mortality ratios (SMR) of lupus patients from 1971 to 2013.

Methods: Our long-term longitudinal cohort followed 1732 patients between 1971-2013. Causes of death were retrieved from death certificates, autopsy reports, hospital records or the records of the family physicians for each patient. They were categorized as atherosclerotic (acute coronary syndrome, ischemic cardiomyopathy, cerebrovascular accident), infection (sepsis), malignancy, active lupus and others. Patients were also categorized according to the age at death in 10-year intervals (15-24, 25-34 etc.). For the calculation of the SMR, data from the general population of Ontario, Canada were used (retrieved from Statistics Canada for the same time period). Statistical analysis was performed with SAS 9.4.

Results: Two hundred and forty-nine patients (205 females) died (infections 24.5%, atherosclerosis 15.7%, active lupus 13.3%, malignancy 9.6%); mean age was 53.2±16.6 years and mean disease duration 15.2±11.7 years. The mean age at death and SMRs for all-cause and cause-specific mortality over the decades are shown in Table 1.

 

Table 1. Mean age at death and Standardized Mortality Ratio* (all-cause and cause-specific) for SLE from 1971 to 2013

 

1971-79

1980-89

1990-99

2000-09

2010-2013

Mean age (y±SD)

42.2±12.9

50.4±16.8

57.2±16.9

54.1±15.9

58.8±14.6

All-cause

13.5 (8.6-18.5)

6.5 (4.9-8.2)

4.7 (3.6-5.8)

3.2 (2.4-4)

2.2 (1.4-3.1)

Atherosclerosis

 

8.3 (3.8-12.8)

6.7 (3.8-9.5)

2.3 (0.8-3.8)

3.2 (0.1-6.3)

Infection

 

14.2 (8-20.4)

6.5 (3.8-9.1)

2.5 (1.2-3.9)

0.9 (0-1.9)

Malignancy

 

14.1 (4.3-23.9)

3 (1.1-4.8)

4.4 (1.5-7.3)

1.4 (0.2-2.7)

*As compared to the general population of Ontario, Canada (1971-2013). Values are given as SMR (95% Confidence Interval)

 

The age-specific SMR was particularly high in younger (15-44 years old) patients [SMR=12.4, 95%CI=9.7-15.1] as compared to the patients who were older than 45 years [SMR=3.1, 95%CI=2.6-3.6]. Details are given in Figure 1.

An analysis of the cause-specific SMR in the age groups 20-39 and >40 showed that younger patients had a higher SMR for all these causes, details in Table 2.

Table 2. Cause-specific Standardized Mortality Ratio for patients 20-39 years old and ≥40 years (1978-2013)

Causes of death

Deaths (20-39 years), n

SMR (20-39 years)

Deaths (≥ 40 years), n

SMR (≥ 40 years)

All cause

58

12.4 (95%CI=9.7-15.1)

191

3.1 (95%CI=2.6-3.6)

Atherosclerosis

3

14.6 (95%CI=0-43.3)

36

4.7 (95%CI=3.3-6)

Infection

30

30.2 (95%CI=14.4-46)

31

3.5 (95%CI=2.5-4.5)

Malignancy

4

31.9 (95%CI0.6-63.1)

20

3 (95%CI=1.9-4.1)

 

Conclusion: The SMR for all-cause and cause-specific mortality has significantly decreased over time, likely reflecting the advances in the management of SLE and atherosclerosis, infections and malignancies. The SMR is particularly high for younger patients (<40 years old) and it remains higher than that of the general population even for the older patients.


Disclosure: K. Tselios, None; D. D. Gladman, None; B. Sheane, None; J. Su, None; M. Urowitz, None.

To cite this abstract in AMA style:

Tselios K, Gladman DD, Sheane B, Su J, Urowitz M. Age- and Cause-Specific Standardized Mortality Ratio of Systemic Lupus Erythematosus Patients in Ontario, Canada over 43 Years (1971-2013) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/age-and-cause-specific-standardized-mortality-ratio-of-systemic-lupus-erythematosus-patients-in-ontario-canada-over-43-years-1971-2013/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/age-and-cause-specific-standardized-mortality-ratio-of-systemic-lupus-erythematosus-patients-in-ontario-canada-over-43-years-1971-2013/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology